Document Detail


A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients.
MedLine Citation:
PMID:  10838499     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Suramin is a polysulfonated naphthylurea with multiple potential mechanisms of action against tumors, including the ability to bind growth factors known to promote tumor angiogenesis. Using an established fixed dosing scheme for the administration of suramin in patients, a pilot study was conducted in patients with progressive, metastatic breast cancer. The primary objective of this trial is to define the effect of suramin on the angiogenic activity in individual patients using in vitro laboratory assays. The secondary objective was to assess the antitumor effect of suramin in a population of metastatic breast cancer patients. No objective tumor responses were observed in any of the 9 patients who received treatment with suramin, however 1 patient did maintain stable disease status. The strength of angiogenic activity present in patient samples was assessed by testing patient plasma in the capillary endothelial cell migration assay. Angiogenic activity followed over time was lowest in patients with the highest suramin concentrations and highest in patients with the lowest suramin concentrations. We conclude that it is feasible to continually monitor the activity of antiangiogenic agents in individual patients without relying on clinical tumor response.
Authors:
W J Gradishar; G Soff; J Liu; A Cisneros; S French; A Rademaker; A B Benson; N Bouck
Related Documents :
11054029 - General state of health and psychological well-being in patients after surgery for urol...
7123159 - Comparison of radioimmunological and conventional acid phosphatase assays in the serum ...
78529 - Flutamide therapy for carcinoma of the prostate.
18281309 - Focal therapy with high-intensity-focused ultrasound in the treatment of localized pros...
19631319 - Comparison of the clinical value of ca 19-9 versus ca 125 for the diagnosis of endometr...
3558869 - Prostatic infiltration in chronic lymphatic leukaemia.
11685159 - Prolonged qrs duration (qrs >/=170 ms) and left axis deviation in the presence of left ...
7787839 - Subpopulations in closed-head injury: preliminary results.
3981709 - Long-term results with transpubic urethroplasty.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Oncology     Volume:  58     ISSN:  0030-2414     ISO Abbreviation:  Oncology     Publication Date:  2000 May 
Date Detail:
Created Date:  2000-07-18     Completed Date:  2000-07-18     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0135054     Medline TA:  Oncology     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  324-33     Citation Subset:  IM    
Copyright Information:
Copyright 2000 S. Karger AG, Basel
Affiliation:
Department of Medicine, Northwestern University Medical School, Chicago, IL, USA. w-gradishar@nwu.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / blood supply*,  drug therapy*,  secondary
Adult
Antineoplastic Agents / administration & dosage,  adverse effects,  therapeutic use*
Breast Neoplasms / blood supply*,  drug therapy*,  pathology
Drug Administration Schedule
Female
Humans
Middle Aged
Neovascularization, Pathologic / drug therapy*
Pilot Projects
Suramin / administration & dosage,  adverse effects,  therapeutic use*
Treatment Outcome
Grant Support
ID/Acronym/Agency:
CA52750/CA/NCI NIH HHS; R01CA71875/CA/NCI NIH HHS; R21CA64487-01/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 145-63-1/Suramin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  RT-PCR suggests human skeletal muscle origin of alveolar soft-part sarcoma.
Next Document:  Clinical significance of expression of estrogen receptor alpha and beta mRNAs in ovarian cancers.